Signal Hereditary Cancer employs multiple DNA analysis methods, along with custom bioinformatics to ensure the highest detection rate for every gene on our panels. Technologies are 99% accurate and delivered via Sema4 Traversa™ NGS-based >6,000 gene medical exome platform with access to clinical biobanking to support future testing.


Does Cancer Run in Your Family?

Knowing your hereditary risk can be powerful information for you and your loved ones. 

We would like to offer the following questionnaire to assist in determining your eligibility for hereditary cancer screening based on industry guidelines.
The answers you provide will help build your medical management plan with your provider.


Pre-test educational video


For patients WITH
a current cancer diagnosis

Build a personalized view of a patient’s disease by integrating germline testing with our somatic and informatics solutions
Identify strategies to reduce the risk of additional cancers
Determine the best treatment, including eligibility for therapies such as PARP inhibitors

For patients WITHOUT
a current cancer diagnosis

Detect inherited changes that increase an individual’s risk for certain cancers
Identify strategies to reduce the risk of developing cancer and aid early detection

For ALL patients
independent of diagnosis

Identify family members with hereditary cancer risk and enable them to access testing
Leverage future clinical advances using bio-banked medical exome data



Delivers data from hybrid capture-based next generation sequencing of ~18,500 genes via Illumina NovaSeq 6000 system. Integrates tumor-normal matched DNA - whole exome sequencing (WES) with RNA-whole transcriptome sequencing (WTS) in one comprehensive test can detect >99% of mutations associated with FDA-approved therapies, standard-of-care treatments, and investigational therapies in clinical trials.
Personalizing Cancer Care with Data-Driven Precision Oncology Solutions through Signal WES/WTS

Identify: Broad range of exome-based sequencing services to identify individuals with increased hereditary cancer risk and detect somatic and germline alterations in those with cancer.

Treat: data-driven insights leveraging real world evidence to guide treatment decisions, including clinical trial matching and inform on patient populations

Monitor: Continuous monitoring of patient’s health in remission and of emerging relevant clinical advances and trials.

Testing may help your provider:
⦁ Determine diagnoses and prognoses for solid and hematological cancers
⦁ Identify and select available targeted therapies, in accordance with level of evidence
⦁ Identify suitability of current clinical trials
⦁ Learn about hereditary contributions to various cancer types as well as non-cancer related conditions outlined in the ACMG recommendations for reporting of secondary findings in clinical exome and genome sequencing (with consent)1,2